XML 64 R52.htm IDEA: XBRL DOCUMENT v3.8.0.1
GOODWILL AND INTANGIBLE ASSETS (Tables)
 12 Months Ended
Dec. 31, 2017
Goodwill And Intangible Assets Schedule Of Significant Goodwill And Intangible Assets Details  
Schedule of Goodwill and Intangible Assets
 
  
Goodwill
US$‘000
    
Development
costs
US$‘000
    
Patents and
licences
US$‘000
    
Other
US$‘000
    
Total
US$‘000
  
Cost
                              
At January 1, 2016
    
82,112
      
109,443
      
9,968
      
33,624
      
235,147
  
Other additions
    
—
      
17,431
      
—
      
77
      
17,508
  
Exchange adjustments
    
(423
)
    
(255
)
    
(43
)
    
—
      
(721
)
 
                                        
At December 31, 2016
    
81,689
      
126,619
      
9,925
      
33,701
      
251,934
  
 
                                        
At January 1, 2017
    
81,689
      
126,619
      
9,925
      
33,701
      
251,934
  
Other additions
    
—
      
10,402
      
22
      
—
      
10,424
  
Disposals
                            
(15
)
    
(15
)
Reclassification
    
—
      
(132
)
    
—
      
132
      
—
  
Exchange adjustments
    
—
      
29
      
—
      
—
      
(29
)
 
                                        
At December 31, 2017
    
81,689
      
136,918
      
9,947
      
33,818
      
262,372
  
 
                                        
Accumulated amortisation and Impairment losses
                                        
At January 1, 2016
    
(29,426
)
    
(20,199
)
    
(6,280
)
    
(17,884
)
    
(73,789
)
Charge for the year
    
—
      
(1,259
)
    
(86
)
    
(1,628
)
    
(2,973
)
Impairment losses
    
(26,489
)
    
(58,195
)
    
(2,948
)
    
(41
)
    
(87,673
)
Exchange adjustments
    
—
      
—
      
(224
)
    
—
      
(224
)
 
                                        
At December 31, 2016
    
(55,915
)
    
(79,653
)
    
(9,538
)
    
(19,553
)
    
(164,659
)
 
                                        
At January 1, 2017
    
(55,915
)
    
(79,653
)
    
(9,538
)
    
(19,553
)
    
(164,659
)
Charge for the year
    
—
      
(1,708
)
    
(17
)
    
(1,578
)
    
(3,303
)
Disposals
    
—
      
—
      
—
      
8
      
8
  
Impairment losses
    
(7,876
)
    
(20,782
)
    
(173
)
    
(836
)
    
(29,667
)
Exchange adjustments
    
—
      
3
      
—
      
—
      
3
  
 
                                        
At December 31, 2017
    
(63,791
)
    
(102,140
)
    
(9,728
)
    
(21,959
)
    
(197,618
)
 
                                        
Carrying amounts
                                        
At December 31, 2017
    
17,898
      
34,778
      
219
      
11,859
      
64,754
  
 
                                        
At December 31, 2016
    
25,774
      
46,966
      
387
      
14,148
      
87,275
  
Schedule of Principal Development Projects
The following represents the costs incurred during each period presented for each of the principal development projects:
 
Product Name
  
2017
US$’000
    
2016
US$’000
  
Premier Instrument for Haemoglobin A1c testing1
    
2,601
      
2,810
  
HIV screening rapid test
    
1,514
      
1,085
  
US Lyme
    
1,156
      
1,003
  
Uni-gold test enhancement
    
1,134
      
1,154
  
G-6-PDH test
    
812
      
-
  
Tri-stat Point-of-Care instrument
    
764
      
678
  
Sjogrens monoclonal antibodies
    
376
      
166
  
HIV screening Africa
    
289
      
650
  
Autoimmune FDA registrations
    
273
      
341
  
Uni-Gold antigen improvement
    
258
      
287
  
Premier Resolution
    
252
      
259
  
Brain Natriuretic Peptide (BNP) assay
    
-
      
2,904
  
Troponin I assay and reader
    
-
      
1,932
  
Cardiac analyser
    
-
      
1,056
  
Enhanced TPHA/CMV
    
-
      
810
  
Malaria Point-of-Care test
    
-
      
411
  
D-Dimer development
    
-
      
332
  
Other projects with spend less than US$250,000 in 2017
    
973
      
1,553
  
Total capitalised development costs
    
10,402
      
17,431
  
 
1
The Premier project entails the development of a High Performance Liquid Chromotography (HPLC) instrument for testing haemoglobin A1c (HbA1c). A number of versions of the instrument are being developed including an Ion Exchange version (Premier Resolution). At December 31, 2017 this project had a total carrying amount of $22,955,000. Amortisation will occur over a 15 year period, commencing on commercialization of each version of the instrument.
Schedule of Impairment Loss Recorded on Discontinued Assets
The table below sets forth the impairment loss recorded for each of the CGU’s at December 31, 2017.
 
 
  
US$’000
  
Trinity Biotech Manufacturing Limited
    
32,561
  
Immco Diagnostics Inc.
    
1,094
  
Clark Laboratories Inc.
    
978
  
Mardx Diagnostic Inc.
    
4,690
  
Phoenix Bio-tech Corp
    
1,801
  
Biopool US Inc.
    
631
  
 
        
Total impairment loss
    
41,755
Schedule of Impairment Loss for Each Class of Asset
The table below sets forth the breakdown of the impairment loss for each class of asset at December 31, 2017:
 
 
  
US$’000
  
Goodwill and other intangible assets (see note 13)
    
29,667
  
Property, plant and equipment (see note 12)
    
10,437
  
Prepayments (see note 17)
    
1,651
  
 
        
Total impairment loss
    
41,755
Schedule of Impairment Loss of Intangible Assets
The impairment loss at December 31, 2017 allocated to goodwill arose on the following CGUs:
 
 
  
US$’000
  
Mardx Diagnostic Inc.
    
3,572
  
Phoenix Bio-tech Corp.
    
1,801
  
Clark Laboratories Inc.
    
978
  
Immco Diagnostics Inc.
    
1,094
  
Blood bank screening business
    
431
  
 
        
Total impairment loss allocated to goodwill
    
7,876
  
 
Schedule of Significant Goodwill
The additional disclosures required for the CGU with significant goodwill are as follows:
 
 
  
Fitzgerald Industries
  
 
  
December 31,
2017
    
December 31,
2016
  
Carrying amount of goodwill (US$’000)
    
12,592
      
12,592
  
Discount rate applied (real pre-tax)
    
17.70
%
    
13.56
%
Excess value-in-use over carrying amount (US$’000)
    
8,397
      
17,762
  
% EBITDA would need to decrease for an impairment to arise
    
30.4
%
    
46.8
%
Long-term growth rate
    
2.0
%
    
2.0
%
Schedule of Internal and External Factors Based on Historical Experience
The assumptions and estimates used are specific to the individual CGU and were derived from a combination of internal and external factors based on historical experience.
 
Intangible Assets with Indefinite Useful lives
(included in other intangibles)
  
December 31, 2017
US$‘000
    
December 31, 2016
US$‘000
  
Fitzgerald Industries International CGU
            
Fitzgerald trade name
    
970
      
970
  
RDI trade name
    
560
      
560
  
Primus Corporation CGU
                
Primus trade name
    
670
      
670
  
Immco Diagnostic CGU
                
Immco Diagnostic trade name
    
3,393
      
3,393
  
Total
    
5,593
      
5,593